Rapid fluid cooling devices and methods for cooling fluids

Information

  • Patent Grant
  • 8808241
  • Patent Number
    8,808,241
  • Date Filed
    Tuesday, October 15, 2013
    10 years ago
  • Date Issued
    Tuesday, August 19, 2014
    9 years ago
Abstract
A cooling device includes a target fluid inlet, a target fluid outlet, an inner conduit, and a chamber surrounding the inner conduit. The inner conduit communicates with the target fluid inlet and the target fluid outlet, and provides a flow path for a target fluid to be cooled. The chamber contains a first endothermic reactant and includes a reactant inlet selectively alterable from a closed state to an open state. When the reactant inlet is in the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs. When the reactant inlet is in the open state, the reactant inlet provides a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant in the chamber for initiating the endothermic reaction and cooling the target fluid in the inner conduit.
Description
TECHNICAL FIELD

The present invention relates generally to fluid cooling devices. More particularly, the present invention relates to the cooling of fluids by endothermic reaction.


BACKGROUND

The cooling of core body temperature, such as for inducing hypothermia, is a medical treatment increasingly being used to treat patients as part of various medical-related procedures. Administering cooled intravenous fluids to induce hypothermia in cardiac arrest patients in the pre-hospital setting has been found to improve the likelihood of those patients being subsequently discharged from the hospital neurologically intact. Induced hypothermia therapy has proven effective in postponing damage to tissues caused by insufficient blood flow and oxygen deprivation. The smaller the time difference between cardiac arrest and induced hypothermia, the higher the likelihood of successful treatment. While there are in-hospital products available for inducing hypothermia, these products are not feasible for use in the pre-hospital setting.


The cooling of intravenous fluids for use in the pre-hospital setting is currently achieved though the use of conventional, bulky refrigeration units or simply ice-filled containers. Primary responders are typically unable to carry both conventional refrigerators and cardiac arrest patients simultaneously on-board a vehicle (e.g., ambulance, helicopter, etc.), or at least it is impractical to do so, for various reasons such as the space required for the refrigeration unit or ice-filled container and the fact that induced hypothermia as a treatment will be indicated in only a small fraction of the emergency situations encountered. Consequently, a second emergency vehicle carrying a refrigeration unit is required to intercept the primary responder and supply the primary responder with cooled intravenous fluids to administer to the patient. Once the cooled fluids are taken out of the refrigerator or ice-filled container, the fluids immediately begin to warm and there is currently no method available to effectively stop the warming process.


In recent years, there has been evidence supporting the use of induced hypothermia therapy in various other medical applications, including cardiac surgery and stroke recovery. As more medical discoveries are made, the potential uses of cooled fluids are likely to increase in both the pre-hospital and in-hospital settings.


In view of the foregoing, there is an ongoing need for cost-effective, efficient, portable, and compact fluid cooling devices for use in the medical field in general, and for use in rapidly cooling intravenous fluids in particular such as for inducing hypothermia in patients requiring medical attention, as well as for use in various non-medical fields.


SUMMARY

To address the foregoing problems, in whole or in part, and/or other problems that may have been observed by persons skilled in the art, the present disclosure provides methods, processes, systems, apparatus, instruments, and/or devices, as described by way of example in implementations set forth below.


According to one implementation, a cooling device includes a target fluid inlet, a target fluid outlet, an inner conduit, and a chamber surrounding the inner conduit. The inner conduit fluidly communicates with the target fluid inlet and the target fluid outlet, and provides a flow path for a target fluid to be cooled. The chamber surrounding the inner conduit contains a first endothermic reactant and includes a reactant inlet selectively alterable from a closed state to an open state. When the reactant inlet is in the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs. When the reactant inlet is in the open state, the reactant inlet provides a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant in the chamber for initiating the endothermic reaction and cooling the target fluid in the inner conduit.


According to another implementation, the reactant inlet of the cooling device may further include a barrier. When the reactant inlet is in the closed state, the barrier may divide the chamber into a first region containing the first endothermic reactant, and a second region containing the second endothermic reactant. The cooling device may include an actuator configured to open the barrier wherein the reactant inlet is altered to the open state.


According to another implementation, the cooling device includes a pressure release valve adapted to communicate with the chamber, wherein the pressure release valve allows flow from the chamber to a receptacle adapted to communicate with the pressure release valve when the pressure in the chamber increases to a predetermined critical pressure.


According to another implementation, at least a portion of the chamber is flexible such that the volume of the chamber is expandable.


According to another implementation, the cooling device includes an insulating material surrounding the chamber.


According to another implementation, the target fluid includes saline solution. In another implementation, the target fluid further includes a therapeutically active drug.


According to another implementation, the reactant inlet comprises a fitting configured for connection to an external source of the second endothermic reactant. In another implementation, the reactant inlet comprises a valve.


According to another implementation, an intravenous target fluid delivery system includes an IV target fluid reservoir, a cooling device, and a cooled IV target fluid receiving tube. The IV target fluid reservoir contains an IV target fluid to be cooled in the cooling device. The IV target fluid reservoir fluidly communicates with a target fluid inlet of the cooling device. The cooled IV target fluid receiving tube fluidly communicates with a target fluid outlet of the cooling device, and is configured for intravenously administering the cooled IV target fluid to a patient.


According to another implementation, the first endothermic reactant includes an inorganic salt such as, for example, ammonium nitrate, ammonium chloride, potassium chloride, etc. The second endothermic reactant may, for example, include water.


According to another implementation, the reactant inlet includes a barrier and in the closed state, the barrier divides the chamber into a first region containing the first endothermic reactant, and a second region containing the second endothermic reactant. In some implementations, an actuator is configured to open the barrier wherein the reactant inlet is altered to an open state. The actuator may be configured to puncture the barrier. Alternatively, the actuator may be configured to move at least a portion of the barrier to create an opening therethrough.


In some implementations, the IV target fluid reservoir may include an IV bag. The cooled IV target fluid receiving tube may include an IV catheter.


According to another implementation, a method is provided for cooling a target fluid. In the method, a target fluid is flowed from a target fluid inlet of a cooling device, through the cooling device, and to a target fluid outlet of the cooling device. While flowing the target fluid, heat is removed from the target fluid by conducting an endothermic reaction in the cooling device.


According to another implementation, a method is provided for treating a patient. A target fluid to be cooled is flowed from a reservoir through a target fluid inlet of a cooling device, and into an inner conduit of the cooling device. The cooling device includes a chamber surrounding the inner conduit and containing a first endothermic reactant. The chamber includes a reactant inlet selectively alterable from a closed state to an open state, wherein in the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs. The endothermic reaction is initiated and the target fluid in the inner conduit is cooled by altering the reactant inlet from the closed state to the open state, wherein the reactant inlet provides a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant in the chamber. The cooled target fluid is flowed through a target fluid outlet of the cooling device into a cooled-fluid-receiving tube. The cooled target fluid is administered to the patient intravenously to reduce the patient's core body temperature.


In some implementations, the target fluid includes saline solution. In further implementations, the target fluid further comprises a therapeutically active drug.


Other devices, apparatus, systems, methods, features and advantages of the invention will be or will become apparent to one with skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description, be within the scope of the invention, and be protected by the accompanying claims.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention can be better understood by referring to the following figures. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention. In the figures, like reference numerals designate corresponding parts throughout the different views.



FIG. 1 is a simplified perspective view of an example of a fluid cooling device according to the present teachings.



FIG. 2 is an exploded perspective view of an example of a fluid cooling device according to the present teachings.



FIG. 3 is a cut-away view of a portion of a chamber surrounding inner helical conduits according to the present teachings.



FIG. 4 is a cross-sectional elevation view of another example of a fluid cooling device according to the present teachings that illustrates a barrier within the chamber.



FIG. 5 is a flow diagram illustrating a method for cooling a target fluid according to the present teachings.



FIG. 6 is a flow diagram illustrating a method for treating a patient according to the present teachings.



FIG. 7 is a schematic of an intravenous target fluid delivery system according to the present teachings.





DETAILED DESCRIPTION

By way of example, FIGS. 1-7 illustrate various implementations of a fluid cooling device, a method for cooling a target fluid, a method for treating a patient, and a related system. The various implementations provide a highly effective, compact, transportable, and efficient solution for rapidly cooling a target fluid for use, as for example, in the pre-hospital setting for intravenously inducing hypothermia or otherwise significantly reducing the core body temperature in cardiac arrest patients as well as for other medical uses and non-medical uses. As noted above, the less the difference in time between cardiac arrest and induced hypothermia, the higher the likelihood of success in subsequently discharging cardiac arrest patients from the hospital neurologically intact. Hypothermia is defined as a body temperature significantly below 37° C., and there are various levels of hypothermia. For example, mild hypothermia is defined as a body temperature of about 34° C., moderate hypothermia is defined as a body temperature of about 23-32° C. and profound hypothermia is defined as a body temperature of about 12-20° C. See Stedman's Medical Dictionary, 26th Edition, 1995. A fluid cooling device consistent with the present teachings has experimentally demonstrated superior performance in providing a cooled target fluid for use in the pre-hospital setting, as compared with the current method of cooling fluids in the pre-hospital setting via conventional refrigeration. For example, a fluid cooling device according to the present teachings has experimentally cooled a target fluid (i.e., saline solution) from room temperature to about 4° C. in about 1.5 to 2.0 minutes, wherein ammonium nitrate and water were utilized as the endothermic reactants in the cooling device. The cooling device according to the present teachings may be sized and configured for compatibility with associated fluid delivery components. For example, the cooling device may be easily connected to standardized intravenous delivery equipment to function as an in-line, on-demand chilling device. All or part of the cooling device may be sterilizable and reusable, or alternatively may be configured as a disposable single-use device.



FIG. 1 is a simplified perspective view of an example of a fluid cooling device 100 according to the present teachings. The cooling device 100 generally includes a target fluid inlet 102 through which a target fluid (e.g., saline solution) to be cooled may enter the cooling device 100, and a target fluid outlet 104 through which the target fluid may exit the cooling device 100. The cooling device 100 also generally includes a chamber 106 surrounding one or more inner conduits (not shown in FIG. 1) between the target fluid inlet 102 and the target fluid outlet 104, and containing a first endothermic reactant (e.g., ammonium nitrate, ammonium chloride, potassium chloride, or the like). The first endothermic reactant may, for example, be packed into the chamber 106 in any suitable form such as powder, pellets, grains, gel, colloid, suspension, liquid, or the like, and may fill the volume in the chamber 106 around the inner conduit or conduits. The inner conduit fluidly communicates with the target fluid inlet 102 and the target fluid outlet 104, and provides one or more flow paths for a target fluid to be cooled. An example of an inner conduit provided as one or more inner helical conduits is described below with respect to FIGS. 2 and 3. Those skilled in the art will appreciate that the inner conduit(s) may be constructed of various materials (e.g., medical grade metals, thermally conductive plastics, and the like) and may include various shapes and cross-sectional areas so as to optimize the available surface area for heat transfer. The target fluid inlet 102 may generally be configured to accommodate the size of any inlet tubing or fitting connected to the target fluid inlet 102. The target fluid outlet 104 may generally be configured to accommodate the size of any outlet tubing or fitting connected to the target fluid outlet 104. The chamber 106 also generally includes a reactant inlet 108 that is selectively alterable from a closed state to an open state. The reactant inlet 108 may include, for example, a Luer-Lock™ port or any valve or fitting switchable between closed and open states, or an openable or frangible barrier. In the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs. In the open state, the reactant inlet 108 provides a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant in the chamber 106 for initiating the endothermic reaction and consequently cooling the target fluid in the inner conduit. As in the case of the first endothermic reactant, the second endothermic reactant may be provided in any suitable form (e.g., solid, semi-solid, colloidal, liquid, etc.). Moreover, the first and/or second endothermic reactant may include any suitable additive that promotes or optimizes the endothermic reaction.


As appreciated by persons skilled in the art, various types of endothermic reactions exist and thus the specific reactants utilized in the cooling device 100 will depend on the particular endothermic reaction being implemented. As examples, ammonium nitrate, ammonium chloride, or potassium chloride may be utilized as the first endothermic reactant, and in each case, water may be utilized as the flowable second endothermic reactant. Other flowable materials may also be suitable for serving as the second endothermic reactant. Generally, the cooling device 100 may employ any combination of reactants that, when combined, result in an endothermic reaction suitable for rapid cooling of a selected target fluid such as, for example, saline solution. The second endothermic reactant may be flowed into the chamber 106 via the reactant inlet 108 by any suitable means such as, for example, utilizing a syringe (not shown) or other external source of reactant. Alternatively, the second endothermic reactant may be provided internally within the cooling device as described by example below in conjunction with FIG. 4. Those skilled in the art will appreciate that in some implementations, the first endothermic reactant may not be pre-loaded in the chamber 106. For example, both the first and second endothermic reactants may be supplied from external sources (e.g., syringes) into the chamber 106 via the reactant inlet 108 in any order (or from two separate reactant inlets) for initiating the endothermic reaction. Having the first endothermic reactant and/or the second endothermic reactant preloaded in the chamber 106 may be particularly useful in implementations in which the cooling device 100 is utilized to rapidly cool intravenous fluids in the pre-hospital setting, for example.


In the present example, the chamber 106 may be constructed of, for example, PVC plastic. At each end of the chamber 106, an end plate 110 may be attached to the chamber 106 by any suitable means, and may be constructed to accommodate the ends of the inner conduits. An end cap 112 may also be secured by any suitable means to the end plate 110 and/or chamber 106 at each end of the chamber 106. The end caps 112 may be tapered or otherwise configured to accommodate the positions of the inner conduit(s) and/or the flow transitions between the inner conduit(s) of the chamber 106 and the target fluid inlet 102 and target fluid outlet 104. Both the end plates 110 and the end caps 112 may be constructed of, for example, ABS plastic. In some implementations, a pressure release valve 114 may optionally be provided to communicate with the chamber 106 such that pressure may release from the chamber 106 to, for example, a receptacle (not shown) adapted to communicate with the pressure release valve 114 when the pressure in the chamber 106 increases to a predetermined critical pressure. For example, if a syringe is used to admit the second endothermic reactant into the chamber 106 via the reactant inlet 108, the pressure release valve 114 may be used to release any excess pressure in the chamber 106 resulting from utilization of the syringe. The use of a receptacle at the pressure release valve 114 maintains the cooling device 100 as a closed system and ensures that the endothermic reactants remain isolated from the environment. Alternatively, element 114 may represent a fluid connection to a flexible chamber that allows for expansion. As a further alternative, at least a portion of the chamber 106 may be flexible to allow for expansion. The chamber 106 may also be surrounded by an insulating material (e.g., polypropylene foam covered in vinyl fabric) to ensure a minimum amount of heat transfer into the cooling device 100 from the outside environment.


The cooling device 100 in FIG. 1 may be used to rapidly, effectively and reliably supply cooled fluids in a manner which does not require the aid of any other device. In one specific yet non-limiting example, the cooling device 100 may be utilized to quickly supply cooled saline solution for intravenous administration to cardiac arrest patients in the pre-hospital setting, so as to reduce the core body temperature of the patients. The cooling device 100 is completely isolated from the external environment, ensuring no contamination of the target liquid, any potential user, and any potential patient while the cooling device 100 is in use. The cooling device 100 may also be utilized in various other settings, e.g., stroke therapy and cardiac surgery. More generally, the cooling device 100 may be utilized in a wide variety of non-medical as well as medical applications for cooling various liquids, gases, vapors, suspensions, etc. The cooling device 100 may be portable, easily storable and easily disposed of after use. The cooling device 100 may be easily connected to input tubing and output tubing for use as an in-line device, as described in further detail below with respect to FIG. 7. The cooling device 100 according to the present teachings may be manufactured in varying sizes and dimensions so as to allow for various temperatures of the target fluid at the target fluid outlet 104 of the cooling device 100. For example, reducing the length of the cooling device 100 may result in a higher temperature of the target fluid at the target fluid outlet 104 as a result of a decrease in surface area utilized for heat transfer. As another example, the cooling device 100 according to the present teachings may be manufactured with varying amounts of the first endothermic reactant so as to allow for various temperatures of the target fluid at the target fluid outlet 104 of the cooling device 100. As yet another example, different cooling devices 100 according to the present teachings may be manufactured with different endothermic reactants so as to allow for various temperatures of the target fluid at the target fluid outlet 104 of the cooling devices 100. In some implementations a target fluid flowing through the cooling device 100 may be cooled from room temperature down to about 3 or 4° C. upon exit from the cooling device 100. The time required for this amount of cooling to occur from the target fluid inlet 102 to the target fluid outlet 104 will depend on a variety of factors, including for example the volume of the chamber 106 and of the reactant loaded therein, the internal diameter and length of the inner conduit(s) and thus the resulting flow rate and residence time of the target fluid in the chamber 106, as well as the specific endothermic reactants utilized.



FIG. 2 is an exploded perspective view of an example of the fluid cooling device 100 discussed above. The fluid cooling device 100 may be utilized as described above with respect to FIG. 1, or as otherwise described in the present teachings. The cooling device 100 also includes the chamber 106 containing the first endothermic reactant. As an example, during assembly the first endothermic reactant may be loaded through one of the initially open ends of the chamber 106. The cooling device 100 may also include an inner conduit 216 through which the target fluid flows from the target fluid inlet 102 to the target fluid outlet 104 in thermal communication with, but fluidly isolated from, the endothermic reactants present in the chamber 106. The inner conduit 216 may be configured to increase the surface area available for heat transfer. Thus, in the present example, the inner conduit 216 may include one or more inner helical conduits 216. When the cooling device 100 is assembled, the inner helical conduits 216 fluidly communicate with the target fluid inlet 102 and the target fluid outlet 104, and provide flow paths for the target fluid to be cooled. When the cooling device 100 is assembled, the chamber 106 surrounds the inner helical conduits 216 as illustrated in FIG. 3. As an alternative to the illustrated helical configuration, the inner conduits 216 may have any other suitable configuration, shape or profile that increases their lengths, increases their outer surface areas, and/or maximizes their thermal contact with the endothermic reactants.


In the present example, the inner helical conduits 216 may be constructed of a thermally conductive material providing adequate heat transfer such as, for example, various metals, e.g., stainless steel, titanium, aluminum, or brass, and certain thermally conductive plastics. In some implementations, the inner helical conduits 216 may be constructed of medical grade conductive materials to ensure against contamination of the target fluid for medical uses. If needed, the inside and/or outside surfaces of the inner helical conduits 216 may be coated with biocompatible or protective barrier films, as appreciated by persons skilled in the art. When the cooling device 100 is assembled, an end plate 110 may be attached to the chamber 106 at each end of the chamber 106, and may be constructed to accommodate the ends of the inner helical conduits 216 and support the inner helical conduits 216 in the chamber 106 in a fixed manner. For instance, in the present example in which three inner helical conduits 216 are utilized, each end plate 110 may include three through-bores respectively communicating with the three inner helical conduits 216 to facilitate flow-splitting from the target fluid inlet 102 and flow-merging to the target fluid outlet 104. An end cap 112 may also be secured by any suitable means (e.g., through the use of an adhesive) to the outside of the end plate 110 and/or the chamber 106 at each end of the chamber 106 when the cooling device 100 is assembled. As also noted above, the chamber 106 may also be surrounded by an insulating material (not specifically shown) to ensure a minimum amount of heat transfer into the cooling device 100 from the outside environment.



FIG. 3 is a cut-away view of a portion of the fluid cooling device 100. Specifically, FIG. 3 illustrates the three inner helical conduits 216 of the present example after installation in the surrounding chamber 106. In this example, the total amount of heat removed from the target fluid as it flows from the inlet side to the outlet side of the chamber 106, and the rate of heat removal, are increased by splitting the flow into more than one inner conduit 216 and by coiling the inner conduits 216 so as to increase their lengths from inlet to outlet. The coiled or helical shapes are but one example; other examples include serpentine shapes and various other multi-turn configurations. As another example, the inner conduits 216 may be provided with cooling fins. Generally, no limitation is placed on the internal diameter(s) of the inner conduit(s) 216, so long as target fluid flow therethrough is unimpeded and travel time is sufficient to ensure a desired amount of heat rejection to the surrounding chamber 106. It can also be seen in FIG. 3 that an ample volume is provided around and between the inner conduits 216 for filling the chamber 106 with the selected endothermic reactants. Upon initiation of the endothermic reaction in the chamber 106, thermal gradients are established from the inner conduits 216 and outward in a multitude of directions.



FIG. 4 is a cross-sectional elevation view of another example of a fluid cooling device 400 according to the present teachings. As in the previous example, the cooling device 400 includes a target fluid inlet 102 and a target fluid outlet 104, which in this example include female and male Luer-type fittings, respectively. The cooling device 400 also includes inner helical conduits 216 fluidly communicating with the target fluid inlet 102 and the target fluid outlet 104 and providing flow paths for the target fluid to be cooled. The cooling device 400 includes a chamber 106 surrounding the inner helical conduits 216 and containing a first endothermic reactant. FIG. 4 also illustrates an insulation layer 436 surrounding the chamber 106 which may be included in the cooling device 400, as described above. The chamber 106 further includes a reactant inlet 414 selectively alterable from a closed state to an open state. In this example, the reactant inlet 414 includes a frangible or openable barrier 420 spanning the internal cross-section of the chamber 106. In the closed state, the barrier 420 may divide the chamber 106 into a first region 432 containing the first endothermic reactant (e.g., ammonium nitrate) and a second region 428 containing the second endothermic reactant (e.g., water). In the closed state, the first endothermic reactant is isolated from the second endothermic reactant by the barrier 420 and thus no endothermic reaction occurs. When the reactant inlet 414 is altered to the open state, such as by breaking, puncturing or otherwise opening the barrier 420, an opening 440 is created to provide a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant for initiating the endothermic reaction and cooling the target fluid in the inner helical conduits 216. Alternatively, the first endothermic reactant may flow from the first region 432 into the second region 428 and thus into contact with the second endothermic reactant. More generally, at least one of the reactants is flowable so that interaction among the reactants occurs after the opening 440 in the barrier 420 has been formed.


In the present example, the barrier 420 may be opened by any suitable user-actuated opening mechanism 424. For example, the mechanism 424 may include a button or knob that, when actuated by the user (e.g., pressed, pulled, slid, rotated, etc.), actuates a puncturing device 438 that breaks the barrier 420 and hence alters the reactant inlet 414 to the open state by creating the opening 440, which allows the first and second endothermic reactants to mix or combine within the chamber 106. As used herein, terms such as “mix” and “combine” encompass any type of contact or interaction between reactants that results in the endothermic reaction utilized as the cooling mechanism according to the present teachings. The exact mechanics of the interaction between the endothermic reactants and the particular reaction kinetics will depend on the type of endothermic reaction conducted in a given implementation, one non-limiting example being the dissolution of certain nitrates or chlorides in a suitable solvent such as water as noted above. As another example, the mechanism 424 may include or operate as a switch that, when actuated by the user, moves the barrier 420 or a portion thereof (e.g., a valve, shutter, or sliding mechanism) to an open state, thereby creating the opening 440 and allowing the second endothermic reactant to flow. In this latter case, the element 438 may represent any suitable mechanical linkage between the mechanism 424 and the barrier 420. For instance, the mechanism 424 may be linked to the barrier 420 such that pushing or pulling the mechanism 424 translates or rotates all or part of the barrier 420 to create the opening 440. As another alternative, the mechanism 424 may be configured such that sliding the mechanism 424 a short distance causes the barrier 420 to open in the manner of a shutter. In all of the foregoing alternatives, the term “breaking” as used in conjunction with altering the barrier 420 encompasses any means by which the opening 440 may be created (e.g., puncturing, moving the barrier 420 or a portion thereof, etc.), and thus in this context terms such as “breaking” and “opening” are used interchangeably. Moreover, in conjunction with breaking or opening the barrier 420, the cooling device 400 may be shaken or agitated by the user to promote the mixing of the reactants.



FIG. 5 is a flow diagram illustrating an example of a method for cooling a target fluid according to the present teachings. The method may be implemented by utilizing a cooling device 100 or 400 such as described above and illustrated in FIGS. 1-4. The first step 502 in the method generally includes flowing the target fluid through a target fluid inlet into an inner conduit or conduits of a cooling device. The target fluid may include, for example, saline solution or any other fluid desired to be cooled in a particular application. The cooling device of the present example may include a chamber surrounding the inner conduit and containing a first endothermic reactant (e.g., ammonium nitrate). The chamber may include a reactant inlet that is selectively alterable from a closed state to an open state. The reactant inlet may be internal or external to the chamber as described above. When the reactant inlet is in the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs. The second step 504 in the present example includes altering the reactant inlet from the closed state to the open state. Consequently, the reactant inlet provides a flow path for enabling the second endothermic reactant (e.g., water) to come into contact with the first endothermic reactant in the chamber for initiating the endothermic reaction and cooling the target fluid in the inner conduit. The target fluid may be cooled to a temperature of, for example, 3 to 4 degrees Celsius, or a variety of other temperatures, depending on the particular application of the method. In some implementations, the second step 504 may be performed prior to carrying out the first step 504, so as to allow the reaction to begin before flowing the target fluid through the target fluid inlet. The third step 506 in the present example includes flowing the target fluid through a target fluid outlet of the cooling device to a selected destination for the cooled target fluid such as into a receiving tube. In one example of one implementation of the present teachings, the cooled-fluid-receiving tube may include IV tubing for use in the medical field.



FIG. 6 is a flow diagram illustrating an example of a method for treating a patient according to the present teachings. The present method may be used, for example, in the treatment of cardiac arrest patients in the pre-hospital or in-hospital settings. The present method may also be used, as another example, in stroke recovery therapy. The first step 602 in the method generally includes flowing a target fluid to be cooled from a reservoir. The target fluid reservoir may include, for example, an IV bag containing a suitable intravenous fluid such as saline solution, and which may additionally include a therapeutically active drug if indicated for the specific situation. Alternatively, a drug may be added to the saline solution after the saline solution has exited a cooling device. The second step 604 in the method includes flowing the target fluid through a target fluid inlet and into an inner conduit(s) of the cooling device, as described above in conjunction with FIG. 5. The third step 606 in the method includes altering a reactant inlet from a closed state to an open state, as described above. As discussed above in conjunction with FIG. 5, the reactant inlet may be altered from the closed state to the open state prior to flowing the target fluid through the target fluid inlet of the cooling device, so as to allow the reaction to commence prior to the target fluid entering the inner conduit(s) of the cooling device. The fourth step 608 in the method includes flowing the target fluid through a target fluid outlet of the cooling device into a cooled-fluid-receiving tube, as described above. The fifth step 610 includes administering to the patient the target fluid in the cooled-fluid-receiving tube intravenously until, for example, a state of hypothermia is reached in the patient. Administering the cooled target fluid to the patient may include adding therapeutically active drugs to the cooled target fluid. As another example of an implementation of the present teachings, the fifth step 610 may include administering the cooled target fluid to the patient to begin induced hypothermia therapy in the pre-hospital setting, although a state of induced hypothermia in the patient may not be reached until the patient is, for example, in the in-hospital setting. As yet another example, the fifth step 610 may include intravenously administering the cooled target fluid to the patient in order to significantly reduce the core body temperature of the patient, with or without the patient ever reaching a state of hypothermia.



FIG. 7 is a schematic of an intravenous target fluid delivery system 700 according to the present teachings. The intravenous target fluid delivery system 700 includes an IV target fluid reservoir 702, a cooling device 704, and a cooled IV target fluid receiving tube 708. The IV target fluid reservoir 702 contains an IV target fluid to be cooled in the cooling device 704. The IV target fluid reservoir 702 may include a standard IV bag, for example. The IV target fluid may include saline solution, and the saline solution may include therapeutically active drugs. The IV target fluid reservoir 702 fluidly communicates with a target fluid inlet of the cooling device 704. The target fluid inlet may generally be configured to accommodate the size of any inlet tubing or fitting that fluidly couples the IV target fluid reservoir 702 to the target fluid inlet of the cooling device 704. The cooling device 704 may generally be configured as discussed above with respect to FIGS. 1 through 4. For example, the cooling device 704 may include the target fluid inlet through which the IV target fluid to be cooled may enter the cooling device 704, and a target fluid outlet through which the cooled IV target fluid may exit the cooling device 704, the target fluid outlet being in fluid communication with the cooled IV target fluid receiving tube 708. The cooling device 704 includes a chamber surrounding one or more inner conduits between the target fluid inlet and the target fluid outlet, and contains a first endothermic reactant. The inner conduit(s) fluidly communicates with the target fluid inlet and the target fluid outlet, and provides one or more flow paths for the IV target fluid to be cooled. The chamber includes a reactant inlet that is selectively alterable from a closed state to an open state. In the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs. In the open state, the reactant inlet provides a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant in the chamber for initiating the endothermic reaction and consequently cooling the IV target fluid in the inner conduit(s). In the present example, the second endothermic reactant may be flowed into the chamber via the reactant inlet by, for example, an external second endothermic reactant supply 706 (e.g., a syringe or other external source of the second endothermic reactant). Alternatively, the second endothermic reactant may be provided internally within the cooling device 704 as described above in conjunction with FIG. 4. In some implementations, the first endothermic reactant may not be preloaded in the chamber and may be flowed into the chamber via the reactant inlet by, for example, an external first endothermic reactant supply. The cooled IV target fluid receiving tube 708 is configured for intravenously administering the cooled IV target fluid to a patient. The cooled IV target fluid receiving tube 708 may include, for example, an IV catheter or any other suitable IV fluid delivery device for administering the cooled IV target fluid to the patient. Therapeutically active drugs may be added to the cooled IV target fluid prior to administering the cooled IV target fluid to the patient. The cooled IV target fluid may be utilized to reduce the core body temperature of the patient. In one example, the cooled IV target fluid may be administered to the patient until the patient reaches a state of hypothermia.


In general, terms such as “communicate” and “in . . . communication with” (for example, a first component “communicates with” or “is in communication with” a second component) are used herein to indicate a structural, functional, mechanical, electrical, signal, optical, magnetic, electromagnetic, ionic or fluidic relationship between two or more components or elements. As such, the fact that one component is said to communicate with a second component is not intended to exclude the possibility that additional components may be present between, and/or operatively associated or engaged with, the first and second components.


It will be understood that various aspects or details of the invention may be changed without departing from the scope of the invention. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation—the invention being defined by the claims.

Claims
  • 1. A cooling device comprising: a target fluid inlet;a target fluid outlet;a plurality of inner conduits fluidly communicating with the target fluid inlet and the target fluid outlet, the plurality of inner conduits providing a plurality of respective flow paths for a target fluid to be cooled; anda chamber surrounding the plurality of inner conduits and containing a first endothermic reactant, the chamber including a reactant inlet selectively alterable from a closed state to an open state, wherein: in the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs; andin the open state, the reactant inlet provides a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant in the chamber for initiating the endothermic reaction and cooling the target fluid in the plurality of inner conduits.
  • 2. The cooling device of claim 1, wherein the reactant inlet comprises a fitting configured for connection to an external source of the second endothermic reactant.
  • 3. The cooling device of claim 1, wherein the first endothermic reactant comprises an inorganic salt.
  • 4. The cooling device of claim 3, wherein the second endothermic reactant comprises water.
  • 5. The cooling device of claim 1, wherein at least a portion of each inner conduit is helical.
  • 6. The cooling device of claim 1, wherein the reactant inlet comprises a barrier and in the closed state, the barrier divides the chamber into a first region containing the first endothermic reactant, and a second region containing the second endothermic reactant.
  • 7. The cooling device of claim 6, further comprising an actuator configured to open the barrier wherein the reactant inlet is altered to the open state.
  • 8. The cooling device of claim 7, wherein the actuator is configured to puncture the barrier.
  • 9. The cooling device of claim 7, wherein the actuator is configured to move at least a portion of the barrier to create an opening therethrough.
  • 10. An intravenous target fluid delivery system comprising: an IV target fluid reservoir including an IV target fluid to be cooled;a cooling device including: a target fluid inlet fluidly communicating with the IV target fluid reservoir;a target fluid outlet;a plurality of inner conduits fluidly communicating with the target fluid inlet and the target fluid outlet, the plurality of inner conduits providing a plurality of respective flow paths for the IV target fluid to be cooled; anda chamber surrounding the plurality of inner conduits and containing a first endothermic reactant, the chamber including a reactant inlet selectively alterable from a closed state to an open state, wherein in the closed state, the first endothermic reactant is isolated from a second endothermic reactant and no endothermic reaction occurs, and in the open state, the reactant inlet provides a flow path for enabling the second endothermic reactant to come into contact with the first endothermic reactant in the chamber for initiating the endothermic reaction and cooling the IV target fluid in the inner conduit; anda cooled IV target fluid receiving tube fluidly communicating with the target fluid outlet, wherein the cooled IV target fluid receiving tube is configured for intravenously administering the cooled IV target fluid to a patient.
  • 11. The intravenous target fluid delivery system of claim 10, wherein the IV target fluid comprises saline solution.
  • 12. The intravenous target fluid delivery system of claim 11, wherein the IV target fluid further comprises a therapeutically active drug.
  • 13. The intravenous target fluid delivery system of claim 10, wherein the reactant inlet comprises a fitting configured for connection to an external source of the second endothermic reactant.
  • 14. The intravenous target fluid delivery system of claim 10, wherein the reactant inlet comprises a barrier and in the closed state, the barrier divides the chamber into a first region containing the first endothermic reactant, and a second region containing the second endothermic reactant.
  • 15. The intravenous target fluid delivery system of claim 14, further comprising an actuator configured to open the barrier wherein the reactant inlet is altered to an open state.
  • 16. The intravenous target fluid delivery system of claim 10, wherein the cooled IV target fluid receiving tube includes an IV catheter.
CROSS REFERENCE TO RELATED APPLICATIONS

This divisional patent application claims the benefit of U.S. patent application Ser. No. 12/711,749, filed Feb. 24, 2010, and titled “RAPID FLUID COOLING DEVICES AND METHODS FOR COOLING FLUIDS,” which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/154,972, filed Feb. 24, 2009, titled “RAPID FLUID COOLING DEVICES AND METHODS FOR COOLING FLUIDS;” the contents of which are incorporated by reference herein in their entireties.

US Referenced Citations (183)
Number Name Date Kind
4065235 Furlong et al. Dec 1977 A
4522640 Jagoe, III Jun 1985 A
4528218 Maione Jul 1985 A
4653577 Noda Mar 1987 A
4697636 Mellsjo Oct 1987 A
4705505 Fried Nov 1987 A
4751119 Yukawa Jun 1988 A
4758562 Adler et al. Jul 1988 A
4986076 Kirk et al. Jan 1991 A
4993237 Bond et al. Feb 1991 A
5062269 Siegel Nov 1991 A
5088302 Tomizawa et al. Feb 1992 A
5219274 Pawlowski et al. Jun 1993 A
5263929 Falcone et al. Nov 1993 A
5395314 Klatz et al. Mar 1995 A
5429762 Kitahara et al. Jul 1995 A
5494416 Gergets Feb 1996 A
5752929 Klatz et al. May 1998 A
5827222 Klatz et al. Oct 1998 A
5840068 Cartledge Nov 1998 A
5913885 Klatz et al. Jun 1999 A
6019783 Philips et al. Feb 2000 A
6033383 Ginsburg Mar 2000 A
6035102 Bakke Mar 2000 A
6042559 Dobak, III Mar 2000 A
6051019 Dobak, III Apr 2000 A
6056932 Von Hippel et al. May 2000 A
6076597 Manning et al. Jun 2000 A
6090132 Fox Jul 2000 A
6096068 Dobak, III et al. Aug 2000 A
6110168 Ginsburg Aug 2000 A
6149624 McShane Nov 2000 A
6149670 Worthen et al. Nov 2000 A
6149676 Ginsburg Nov 2000 A
6149677 Dobak, III Nov 2000 A
6158994 Mulcahy Dec 2000 A
6224624 Lasheras et al. May 2001 B1
6231594 Dae May 2001 B1
6231595 Dobak, III May 2001 B1
6233945 Kohout May 2001 B1
6264679 Keller et al. Jul 2001 B1
6270324 Sullivan et al. Aug 2001 B1
6306161 Ginsburg Oct 2001 B1
6440158 Saab Aug 2002 B1
6454792 Noda et al. Sep 2002 B1
6478812 Dobak, III et al. Nov 2002 B2
6527798 Ginsburg et al. Mar 2003 B2
6547811 Becker et al. Apr 2003 B1
6554791 Cartledge et al. Apr 2003 B1
6572640 Balding et al. Jun 2003 B1
6582455 Dobak, III et al. Jun 2003 B1
6607517 Dae et al. Aug 2003 B1
6620131 Pham et al. Sep 2003 B2
6623514 Chin Sep 2003 B1
6656209 Ginsburg Dec 2003 B1
6702839 Dae et al. Mar 2004 B1
6736790 Barbut et al. May 2004 B2
6752786 Callister Jun 2004 B2
6878156 Noda Apr 2005 B1
6905509 Dobak, III et al. Jun 2005 B2
6939520 Filippi et al. Sep 2005 B2
6962601 Becker et al. Nov 2005 B2
7008444 Dae et al. Mar 2006 B2
7008445 Lennox Mar 2006 B2
7014651 Worthen et al. Mar 2006 B2
7052509 Lennox et al. May 2006 B2
7077825 Stull Jul 2006 B1
7144418 Lennox Dec 2006 B1
7231771 McMurry et al. Jun 2007 B2
7303328 Faraldi et al. Dec 2007 B2
7311724 Ginsburg Dec 2007 B1
7350361 Maxwell et al. Apr 2008 B2
7422600 Dobak, III Sep 2008 B2
7422601 Becker et al. Sep 2008 B2
7449018 Kramer Nov 2008 B2
7507250 Lennox Mar 2009 B2
7571621 Dietschi et al. Aug 2009 B2
7597136 Kite et al. Oct 2009 B2
7758623 Dzeng et al. Jul 2010 B2
7806915 Scott et al. Oct 2010 B2
7827815 Carson et al. Nov 2010 B2
7867266 Collins Jan 2011 B2
7989508 Hecht Aug 2011 B2
8047010 Carson et al. Nov 2011 B2
8091337 Tepesch Jan 2012 B2
8100123 Belson Jan 2012 B2
8117854 Lampe et al. Feb 2012 B2
8157794 Dobak et al. Apr 2012 B2
8231664 Kulstad et al. Jul 2012 B2
8257340 Saab Sep 2012 B2
8308787 Kreck Nov 2012 B2
8343202 Magers Jan 2013 B2
8388571 Joshi et al. Mar 2013 B2
8388578 Joshi et al. Mar 2013 B2
8402968 Belson Mar 2013 B2
8409265 Keller et al. Apr 2013 B2
8439960 Burnett et al. May 2013 B2
20010001830 Dobak et al. May 2001 A1
20010001831 Dobak et al. May 2001 A1
20010007951 Dobak, III Jul 2001 A1
20010016763 Lasheras et al. Aug 2001 A1
20020004675 Lasheras Jan 2002 A1
20020045852 Saab Apr 2002 A1
20020082671 Magers et al. Jun 2002 A1
20020095201 Worthen et al. Jul 2002 A1
20020111584 Walker et al. Aug 2002 A1
20020111657 Dae et al. Aug 2002 A1
20020116039 Walker et al. Aug 2002 A1
20020138122 Worthen et al. Sep 2002 A1
20020151845 Werneth Oct 2002 A1
20020151942 Walker et al. Oct 2002 A1
20020151944 Pham et al. Oct 2002 A1
20020161349 Allers et al. Oct 2002 A1
20020161351 Samson et al. Oct 2002 A1
20020183816 Tzeng et al. Dec 2002 A1
20020198579 Khanna Dec 2002 A1
20030004456 Saab Jan 2003 A1
20030060761 Evans et al. Mar 2003 A1
20030078641 Dobak, III Apr 2003 A1
20030130651 Lennox Jul 2003 A1
20030139791 Dobak, III Jul 2003 A1
20030216746 Worthen et al. Nov 2003 A1
20040073280 Dae et al. Apr 2004 A1
20040158191 Samson et al. Aug 2004 A1
20040199114 Noda Oct 2004 A1
20040199229 Lasheras Oct 2004 A1
20040210281 Dzeng et al. Oct 2004 A1
20040215163 Walker et al. Oct 2004 A1
20040215297 Collins Oct 2004 A1
20040220647 Noda Nov 2004 A1
20050004503 Samson et al. Jan 2005 A1
20050027244 Eidenschink Feb 2005 A1
20050027281 Lennox Feb 2005 A1
20050033391 Worthen et al. Feb 2005 A1
20050076924 Dobak, III Apr 2005 A1
20050080374 Esch et al. Apr 2005 A1
20050096714 Freedman et al. May 2005 A1
20050107741 Harrison et al. May 2005 A1
20050120734 Yon Jun 2005 A1
20050274118 McMurry et al. Dec 2005 A1
20060064146 Collins Mar 2006 A1
20060136023 Dobak, III Jun 2006 A1
20060142827 Willard et al. Jun 2006 A1
20060161232 Kasza et al. Jul 2006 A1
20060167398 Solar et al. Jul 2006 A1
20060184231 Rucker Aug 2006 A1
20060293732 Collins et al. Dec 2006 A1
20070000278 Collins et al. Jan 2007 A1
20070005121 Khanna Jan 2007 A1
20070050002 Elefteriades Mar 2007 A1
20070191918 MacHold et al. Aug 2007 A1
20070244434 Noda et al. Oct 2007 A1
20070244531 Noda et al. Oct 2007 A1
20070293921 Noda et al. Dec 2007 A1
20080027383 Nahhas Jan 2008 A1
20080046046 Ginsburg Feb 2008 A1
20080114431 Ginsburg May 2008 A1
20080221651 Dobak Sep 2008 A1
20080271476 Langguth Nov 2008 A1
20080296190 Marak et al. Dec 2008 A1
20090265113 Kimball Oct 2009 A1
20100030190 Singh Feb 2010 A1
20100104493 Hyde et al. Apr 2010 A1
20100121159 Burnett et al. May 2010 A1
20100160705 Kosters et al. Jun 2010 A1
20100204765 Hall et al. Aug 2010 A1
20100324483 Rozenberg et al. Dec 2010 A1
20110029050 Elefteriades et al. Feb 2011 A1
20110066217 Diller et al. Mar 2011 A1
20110082423 Joshi et al. Apr 2011 A1
20110125233 Shen et al. May 2011 A1
20110137248 Winter Jun 2011 A1
20110137249 Collins et al. Jun 2011 A1
20120095536 Machold et al. Apr 2012 A1
20120095537 Hall et al. Apr 2012 A1
20120116487 Burnett et al. May 2012 A1
20120123509 Merrill et al. May 2012 A1
20120172781 Wang Jul 2012 A1
20120221082 Khanna Aug 2012 A1
20130030411 Kreck et al. Jan 2013 A1
20130046232 Walker et al. Feb 2013 A1
20130046365 Noda et al. Feb 2013 A1
20130060311 Noda et al. Mar 2013 A1
Foreign Referenced Citations (62)
Number Date Country
199946852 Jan 2000 AU
2007201161 Apr 2007 AU
2538331 Mar 2003 CN
102309786 Jan 2012 CN
1028679 Aug 2000 EP
1049412 Nov 2000 EP
1205167 May 2002 EP
1406566 Apr 2004 EP
2514453 Oct 2012 EP
1245824 May 1992 IT
2008154751 Jul 2008 JP
04610825 Jan 2011 JP
0009054 Feb 2000 WO
0010494 Mar 2000 WO
0047145 Aug 2000 WO
0053135 Sep 2000 WO
0057823 Oct 2000 WO
0059419 Oct 2000 WO
0062837 Oct 2000 WO
0110323 Feb 2001 WO
0110365 Feb 2001 WO
0112061 Feb 2001 WO
0126590 Apr 2001 WO
0136035 May 2001 WO
0141708 Jun 2001 WO
0143661 Jun 2001 WO
0149236 Jul 2001 WO
0152781 Jul 2001 WO
0156517 Aug 2001 WO
0158397 Aug 2001 WO
0166052 Sep 2001 WO
0174276 Oct 2001 WO
0195840 Dec 2001 WO
0226176 Apr 2002 WO
0226285 Apr 2002 WO
0228458 Apr 2002 WO
0236180 May 2002 WO
0238091 May 2002 WO
02058606 Aug 2002 WO
02068928 Sep 2002 WO
03015672 Feb 2003 WO
03015673 Feb 2003 WO
03028796 Apr 2003 WO
03037158 May 2003 WO
03066137 Aug 2003 WO
2004023982 May 2004 WO
2004075949 Sep 2004 WO
2005112843 Dec 2005 WO
2007002946 Jan 2007 WO
2007005026 Jan 2007 WO
2007078463 Jul 2007 WO
2009023797 Feb 2009 WO
2009094601 Jul 2009 WO
2009102803 Aug 2009 WO
2009124552 Oct 2009 WO
2009124553 Oct 2009 WO
2010111778 Oct 2010 WO
2011103208 Aug 2011 WO
2011156565 Dec 2011 WO
2012006184 Jan 2012 WO
2012012740 Jan 2012 WO
2013049637 Apr 2013 WO
Non-Patent Literature Citations (8)
Entry
Hypothermia after Cardiac Arrest Study Group, (2002), Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. The New England Journal of Medicine, 346(8), 549-556.
Bernard, S.A., Gray, T.W., Buist, M.D., Jones, B.M., Silvester, W., Guthridge, G., et al. (2002), Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. The New England Journal of Medicine, 346(8), 557-563.
Keller, E. Imhof, Ho G., Gasser, S., Terzic, A., & Yonekawa, Y. (2003). Endovascular cooling with heat exchange catheters: A new method to induce and maintain hypothermia. Intensive Care Medicine, 29(6), 939-943.
Nolan, J.P., Morley, P.T., Hock, T.L., Hicking, R.W., & Advancement Life Support Task Force of the International Liaison Committee on Resuscitation. (2003). Therapeutic hypothermia after cardiac arrest. An advisory statement by the advancement life support task force of the international liaison committee on resuscitation. Resuscitation, 57(3), 231-235.
Al-Senani, F.M., Grattagnino, C., Grotta, J.C., Saiki, R., Wood, D., Chung, W., et al. (2004). A prospective, multicenter pilot study to evaluate the feasibility and safety of using the CoolGard(tm) system and Icy(tm) catheter following cardiac arrest. Resuscitation, 62(2), 143-150.
Diringer, M.N., & Neurocritical Care Fever Reduction Trial Group (2004). Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system, Critical Care Medicine, 32(2), 559-564.
Huppman, S., Johnson, J. Kang, S. & Wacker, E.; Intravenous Cooling System to Induce Mild Hypothermia; University of Pitsburgh Senior Design, BioE 1160-1161; Apr. 10, 2007, 27 pages.
Huppman, S., Johnson, J. Kang, S. & Wacker, E.; IV Cooling System for Hypothermia; SBIR Proposal; Apr. 17, 2007; 22 pages.
Related Publications (1)
Number Date Country
20140046257 A1 Feb 2014 US
Provisional Applications (1)
Number Date Country
61154972 Feb 2009 US
Divisions (1)
Number Date Country
Parent 12711749 Feb 2010 US
Child 14054315 US